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Abstract
X-linked alpha thalassaemia mental retardation (ATR-X) syndrome in males is associated with
profound developmental delay, facial dysmorphism, genital abnormalities and alpha thalassaemia.
Female carriers are usually physically and intellectually normal. So far, 168 patients have been
reported. Language is usually very limited. Seizures occur in about one third of the cases. While
many patients are affectionate with their caregivers, some exhibit autistic-like behaviour. Patients
present with facial hypotonia and a characteristic mouth. Genital abnormalities are observed in 80%
of children and range from undescended testes to ambiguous genitalia. Alpha-thalassaemia is not
always present. This syndrome is X-linked recessive and results from mutations in the ATRX gene.
This gene encodes the widely expressed ATRX protein. ATRX mutations cause diverse changes in
the pattern of DNA methylation at heterochromatic loci but it is not yet known whether this is
responsible for the clinical phenotype. The diagnosis can be established by detection of alpha
thalassaemia, identification of ATRX gene mutations, ATRX protein studies and X-inactivation
studies. Genetic counselling can be offered to families. Management is multidisciplinary: young
children must be carefully monitored for gastro-oesophageal reflux as it may cause death. A
number of individuals with ATR-X are fit and well in their 30s and 40s.
Disease name and synonyms
X-linked alpha thalassaemia mental retardation (ATR-X)
syndrome.
Definition/diagnostic criteria
Since the identification of the causative gene (ATRX) and
the advent of procedures to confirm the diagnosis by
molecular means, it has become clear that there are few
sine qua non diagnostic features. Generally, however,
affected individuals have moderate to profound learning
difficulties associated with a severe expressive language
disorder (95% of cases have severe to profound mental
retardation (MR)). Most cases (>90%) will have a charac-
teristic and recognisable facial gestalt during infancy.
Some degree of genital abnormality is common (80%).
Many affected individuals (90%) will have haematologi-
cal signs of alpha thalassaemia. Other features include:
skeletal abnormalities (90%), microcephaly (75%), short
stature (65%), seizures (30%), cardiac defects (20%),
renal/urinary abnormalities (15%).
Epidemiology
The prevalence of ATR-X in the general population is
unknown. So far, 168 patients have been reported. An
estimate for the prevalence is <1-9/1,000,000.
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Clinical description
Psychomotor retardation and central nervous system
Most cases of ATR-X syndrome have global developmen-
tal delay. However, even in less severely affected cases,
where general performance may be classified as in the
moderate level, expressive language is usually very lim-
ited.
In early childhood generalised hypotonia is common and
all milestones are delayed. More severely affected patients
do not walk until later in childhood and some never
ambulate. Most have no speech, although an increasing
number of individuals are being identified who use a few
words or signs. The most severe cases may only have situ-
ational understanding, and most are dependent on others
for almost all daily activities. More recent reports, how-
ever, point to a wider spectrum of intellectual handicap
than previously thought. A mutation in the ATRX gene has
recently been identified in family originally described by
Carpenter and colleagues [1]. All affected males had mod-
erate MR and exhibited expressive language delay, though
no psychometric evaluation was available. Guerrini and
colleagues reported a mutation in an Italian family with
four affected male cousins, one had profound MR,
whereas the others had an intellectual quotient (IQ) of 41,
56 and 58 [2]. The basis for this marked variation is
unknown.
Generally, affected individuals continue to acquire new
skills, though a brief period of neurological deterioration
has been reported in three cases. In one report, electroen-
cephalogram (EEG) changes were consistent with
encephalitis [3]. The family originally reported by Holmes
and Gang [4] was subsequently shown to have an ATRX
mutation [5]. The reported family consisted of an infant
and two maternal uncles with microcephaly, large fonta-
nel, hypotonic face with short nose and anteverted nares,
epicanthus, club foot deformity, and retarded psychomo-
tor development. All three affected males from this family
died in childhood and the death of one was attributed to
encephalitis.
With age, affected individuals often develop a tendency
toward spasticity. One report described a family with an
ATRX mutation where affected members had spastic para-
plegia from birth [6].
Seizures occur in approximately one third of cases and
most frequently are clonic/tonic or myoclonic in nature. A
number of parents have reported jerking movements,
which are not associated with epileptiform activity on
EEG.
Assessment of vision and hearing is difficult. Vision usu-
ally appears normal, although two patients have been
reported as blind. Optic atrophy or pale discs are com-
monly noted, as are refractive errors (especially myopia).
Sensorineural deafness and alpha thalassaemia were pre-
viously considered as features that distinguishes ATR-X
syndrome from the allelic condition Juberg-Marsidi syn-
drome [7]. However, of the 13 cases with a documented
sensorineural hearing deficit, seven had alpha thalassae-
mia suggesting the two conditions are part of a single con-
tinuum.
Although the head circumference is usually normal at
birth, post-natal microcephaly usually develops. Macro-
cephaly has not been reported.
Computed tomography (CT) and magnetic resonance
imaging (MRI) do not generally reveal remarkable find-
ings, although mild cerebral atrophy may be seen. In two
cases, partial or complete agenesis of the corpus callosum
was reported. Autopsy reports were available for only
three cases. The brain was small in each; in two cases the
morphology was normal, but in the remaining case the
right temporal gyri were indistinct and there was hypopla-
sia of the cerebral white matter.
Behavioural phenotype
No systematic study of behaviour has been carried out for
ATR-X syndrome. Consequently, most reports of behav-
ioural characteristics are anecdotal. Nevertheless, a
thumbnail sketch of the mannerisms of this condition is
slowly emerging [8,9] and may be useful for diagnosis.
The subjects are usually described by their parents as con-
tent and of a happy disposition. Affected individuals
exhibit a wide range of emotions that are usually appro-
priate to their circumstances. There have been reports,
however, of unprovoked emotional outbursts with sus-
tained laughing or crying. There may be emotional fluctu-
ation with sudden switches between almost manic-like
excitement or agitation, and withdrawal and depression.
In several instances, the episodes of crying have been
thought to be associated with pain, possibly of a gastroin-
testinal origin (see below).
Whereas many of the individuals are affectionate to their
caregivers and appreciate physical contact, some patients
exhibit autistic-like behaviour: patients appear to be in a
world of their own, show little interest or even recognition
of those around them, and avoid eye contact. The latter
behaviour may be associated with an unusual and persist-
ent posture.
Affected individuals may be restless, exhibiting chore-
oathetotic-like movements. Frequently, they put their
hands into their mouths and may induce vomiting. Some-
times, they engage in self-injurious behaviour, biting orOrphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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hitting themselves. They may hit, push or squeeze their
neck with their hands to the point of cyanosis, a state they
may also achieve through breath-holding. They may
exhibit obsessional behaviour such as spinning on one
spot while gazing into a light. Repetitive stereotypic move-
ments may be manifest and these may vary from pill-roll-
ing to hand flapping. This characteristic behaviour is
reminiscent of Angelman syndrome and may lead to diag-
nostic confusion.
Facial anomalies
Distinctive facial traits are most readily recognised in early
childhood and the gestalt is probably secondary to facial
hypotonia (Figure 1). The frontal hair is often upswept,
there is telecanthus, epicanthic folds, flat nasal bridge and
mid-face hypoplasia, and a small triangular upturned
nose with the alae nasi extending below the columella
and septum. The upper lip is tented, the lower lip full and
everted. The frontal incisors are frequently widely spaced,
the tongue protrudes and there is prodigious dribbling.
The ears may be simple, slightly low set and posteriorly
rotated.
Genital abnormalities
Genital abnormalities are seen in 80% of children. These
may be very mild (e.g., undescended testes or deficient
prepuce), but the spectrum of abnormality extends
through hypospadias and micropenis to ambiguous
female external genitalia. The most severely affected chil-
dren, who are clinically defined as male pseudohermaph-
rodites, are usually raised as females. In such cases there
are no Mullerian structures present, and intra-abdominal,
dysgenetic testes or streak gonads have been found
[10,11]. Of particular interest is the finding that these
abnormalities breed true within families [12]. Puberty is
frequently delayed and, in a few cases, appears to be
arrested. Curiously, premature adrenarche has been noted
in two children ([13] and unpublished observation).
Skeletal abnormalities
In a series of 45 cases, a wide range of relatively mild skel-
etal abnormalities were noted, some of which were prob-
ably secondary to hypotonia and immobility [14]. Fixed
flexion deformities, particularly of the fingers, were com-
mon. Other abnormalities of the fingers and toes were
also observed: clinodactyly, brachydactyly, tapering of the
fingers, drum stick phalanges, cutaneous syndactyly, over-
lapping of the digits, and a single case with a bifid thumb.
Foot deformities occured in 29% of cases and include pes
planus, talipes equinovarus and talipes calcaneovalgus.
Almost a third of the cases had kyphosis and/or scoliosis,
and chest wall deformity was seen in 10 cases. Sacral dim-
ples were present in three cases, radiological spina bifida
in two cases and other abnormalities of the vertebrae in
five cases. Only a few of the cases had a thorough radio-
logical investigation. In those investigated, the most com-
mon findings were delayed bone age and coxa valga. Short
stature was seen in two-thirds of cases. Longitudinal data
were available for only a few cases. As noted previously, in
some patients growth retardation is apparent throughout
life, whereas in others it manifests at a later stage, e.g. at
the time of the pubertal growth spurt.
Miscellaneous abnormalities
Recurrent vomiting, regurgitation or gastro-oesophageal
reflux, particularly in early childhood, are common find-
ings. In a recent study involving a pair of affected non-
identical twins, a barium meal revealed that both children
had episodic gastric pseudovolvulus. In this condition the
stomach does not have the normal system of peritoneal
ligaments and has a propensity to torsion around itself
leading to gastric outlet obstruction and secondary gastro-
Child of 8 yrs with the characteristic facial features of ATR-X  syndrome Figure 1
Child of 8 yrs with the characteristic facial features of ATR-X 
syndrome. Note the upswept frontal hair line, hypertelorism, 
epicanthic folds, flat nasal bridge, small triangular upturned 
nose, tented upper lip, everted lower lip and hypotonic 
facies.Orphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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oesophageal reflux [15]. An apparent reluctance to swal-
low has been reported by several parents and probably
reflects the dyscoordinated swallowing that was observed
radiologically in two well-studied cases (unpublished
data). The tendency for aspiration is commonly impli-
cated as a cause of death in early childhood. Excessive
drooling is very common, as is frequent eructation. Con-
stipation occurs often, and in some individuals is a major
management problem. Martucciello et al. [15] demon-
strated ultra-short Hirshsprung's disease and colonic
hypoganglionosis in two affected children. The authors
reviewed 128 cases of ATR-X and found that hospital
admissions for recurrent ileus were reported in two cases
and that reduced intestinal mobility was observed radio-
logically in four cases. This may be a consequence of a
widespread abnormality in the enteric nervous system,
leading to abnormal gut motility. Two of the patients
required partial resection of the ileum after developing
ischaemia of the small bowel, which in one case was
attributed to a volvulus. Volvulus was also reported in an
additional case. One child required a right hemicolec-
tomy following an episode of necrotising enterocolitis at
13 days of age (reviewed in [15]).
Evidence suggests that affected individuals are susceptible
to peptic ulceration. Oesophagitis, oesophageal stricture
and peptic ulcer have observed endoscopically in single
cases. In five cases, an upper gastrointestinal bleed was
observed, one of which required transfusion (haemo-
globin, 5 g/dl) [14,15]. Pain resulting from peptic ulcera-
tion is one possible explanation for the episodes of
persistent crying and food refusal reported by a number of
parents. A wide range of cardiac abnormalities have been
noted: septal defects (10 cases); patent ductus arteriosus
(six cases); pulmonary stenosis (three cases); aortic steno-
sis (two cases); tetralogy of Fallot (two cases) and single
cases of transposition of the great arteries, dextracardia
with situs solitus and aortic regurgitation ([14] and
unpublished data).
Renal abnormalities (hydronephrosis, renal hypoplasia or
agenesis, polycystic kidney, vesico-ureteric reflux) may
present with recurrent urinary tract infections.
Haematology
Although the presence of alpha thalassaemia was initially
one of the defining elements of the syndrome, it is clear
that there is considerable variation in the haematological
manifestations associated with ATRX  mutations. A
number of families have been identified in which some or
all of the affected members show no signs of alpha thalas-
saemia [16,17]. The test for alpha thalassaemia is simple
and, when positive, quickly establishes the diagnosis (see
diagnostic methods). However, the haematological find-
ings are often surprisingly normal considering the pres-
ence of alpha thalassaemia. Neither haemoglobin
concentration nor mean cell haemoglobin concentration
are as severely affected as in the classical forms of alpha
thalassaemia associated with cis-acting mutations in the
alpha globin complex. This discrepancy probably reflects
the different pathophysiology of the conditions.
Aetiology
The gene involved in the disease, ATRX, lies at Xq13.3
[18]. It spans about 300 kb of genomic DNA and contains
36 exons [19]. It encodes at least two alternatively spliced
~10.5 kb mRNA transcripts which differ at their 5' ends
and are predicted to give rise to slightly different proteins
of 265 and 280 kD respectively. A further transcript of ~7
kb represents an isoform which retains intron 11 and
truncates at this point. This gives rise to a truncated pro-
tein isoform, ATRXt, which is conserved between mouse
and man [20]. The protein belongs to the SNF2 family of
helicase/ATPases, members of which are involved in a
wide variety of cellular functions including the regulation
of transcription (SNF2, MOT1 and brahma), control of
the cell cycle (NPS1), DNA repair (RAD16, RAD54 and
ERCC6) and mitotic chromosome segregation (lodestar).
It is believed that their function is to facilitate these proc-
esses by remodelling chromatin. Another important fea-
ture of the ATRX protein is the presence, at the N terminal,
of a zinc finger domain (called the ADD domain), which
is related to sequences seen in the DNA methyltransferase
3 (DNMT3) family of de novo DNA methyltransferases
[21]. It is not known whether this domain is involved in
protein or DNA interactions. The majority of naturally
occurring mutations in the ATRX gene occur in the ADD
and helicase domains [22]. It is likely that all the muta-
tions are associated with reduced function.
The function of the ATRX protein is unknown, but the fact
that alpha globin expression is perturbed in the patients
suggests that it may play a role in gene expression. Protein
studies have shown that ATRX is a nuclear protein with a
punctate staining pattern [23]. In mouse cells, and to a
lesser extent in human cells, the majority of the protein is
associated with DAPI-bright regions of the nucleus, which
are known to represent pericentromeric heterochromatin.
Evidence is also accumulating for an interaction between
ATRX and another heterochromatic protein, HP1 [24,25].
ATRX is also found in promyelocytic leukaemia nuclear
bodies, where it interacts with the transcription cofactor
Daxx [26,27]. One additional striking finding in human
metaphase preparations is that anti-ATRX antibodies con-
sistently localise to the short arms of acrocentric chromo-
somes and co-localise with a transcription factor
(upstream binding factor) that is known to bind the ribos-
omal DNA (rDNA) arrays in nucleolar organiser regions
[23].Orphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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The effects of ATRX mutations on the chromatin structure
of the rDNA arrays located in these regions have been
studied. Although no gross changes in DNAase1, micro-
coccal nuclease or endonuclease accessibility were
detected, striking differences were noted in the pattern of
rDNA methylation between normal controls and patients
with ATR-X syndrome [28]. In normal individuals,
approximately 20% of the transcribed units were methyl-
ated; whereas, in ATR-X patients, a substantial number of
these rDNA genes were unmethylated. An extensive survey
of the genome has identified two additional sequences
that are abnormally methylated in ATR-X patients. Y-spe-
cific repeats (DYZ2) are almost all methylated in ATR-X
patients, while ~6% are unmethylated in peripheral blood
of normal individuals. Subtle changes in the pattern of
methylation have also been observed in the TelBam3.4
family of repeats that are mainly found in the subtelom-
eric regions. It is not clear whether the perturbation of
methylation that is observed in affected individuals plays
a role in the aetiology of the condition. To date, no change
in the pattern of methylation has been detected in the
alpha globin gene cluster that might explain the reduced
expression of the alpha globin genes compared with
expression of the beta globin genes.
In the knock-out mouse model, absence of ATRX is lethal
early in embryogenesis indicating that ATRX is essential
for development [29]. In conditional knock-out mice,
where only the forebrain is affected, there was normal
proliferation of cortical progenitors but widespread apop-
tosis associated with the differentiation of the cortical
neurones, which led to a reduction in forebrain size [30].
Genotype/phenotype correlations
Since the discovery of the ATRX gene, most new cases have
been defined on the basis of severe MR with the typical
facial appearance (see clinical description) associated
with a mutation in the ATRX  gene. This allows a less
biased evaluation of the effect of ATRX mutations on the
commonly associated clinical manifestations. The severity
of three aspects of the phenotype, mental retardation,
genital abnormality and alpha thalassaemia, is quantifia-
ble to some degree.
The greatest variation in intellectual handicap is associ-
ated with a truncating mutation at the N-terminus of the
protein [2]. The same mutation has also been described in
the Chudley-Lowry family [31] in which the phenotype
was milder than that usually associated with ATRX muta-
tions. Protein analysis by Western blotting has shown that
small amounts of full-length protein are present in each
patient [31,32]. There is some debate about how this phe-
notypic rescue is achieved: the possibilities being skipping
of the mutation by initiation at a downstream methionine
or by alternative splicing. There is, however, no obvious
correlation between the degree of retardation and the
amount of full-length protein.
There are now eight different mutations associated with
the most severe urogenital abnormalities. Five of these
mutations lead to the production of a truncated protein
resulting in the loss of the C-terminal domain, including
a conserved element and polyglutamine tract. From the
available data, it appears that in the absence of the C-ter-
minal domain, severe urogenital abnormalities are likely
(though not inevitable as one mutation in this region was
associated only with cryptorchidism) suggesting that this
region may play a specific role in urogenital development.
At other mutation sites, however, there is no obvious link
between phenotype and genotype and there is considera-
ble variation in the degree of abnormality seen in individ-
uals with identical mutations.
The relationship between ATRX mutations and alpha tha-
lassaemia is unclear. Past reports are inevitably biased as
the presence of excess beta chains (HbH inclusions) was
originally used to define the ATR-X syndrome. However,
inclusions may not appear until there is a 30–40% reduc-
tion in alpha chain synthesis [33]. Thus, some patients do
not have HbH inclusions [16,17,34], but this does not
rule out down-regulation of alpha globin expression. Fur-
thermore, comparison of the 32 cases from 26 pedigrees
with the common 736C>T mutation shows a variation in
the frequency of HbH inclusions from 0 to 14%. This var-
iable frequency of cells with HbH inclusions indicates
considerable variability in the degree to which alpha
globin synthesis is affected by the 736C>T mutations. The
fact that patients with identical mutations may have very
different, albeit stable, degrees of alpha thalassaemia sug-
gests that the effect of the ATRX protein on alpha globin
expression may be modified by other genetic factors.
Diagnostic methods
Detection of alpha thalassaemia
The most sensitive test uses light microscopy to detect red
cells containing HbH inclusions after incubation of
venous blood with 1% brilliant cresyl blue in isotonic
saline for 4–24 hours at room temperature (Figure 2).
HbH is unstable and cells with inclusions may be more
difficult to find in older blood samples. When the family
history and phenotype are highly indicative of ATR-X syn-
drome, a careful search for inclusions should be per-
formed in all affected individuals and repeated, if
necessary, as inclusions may be very infrequent. It is
important to note that, in most cases of ATR-X, the
amounts of HbH are too low to be detected by electro-
phoresis. The haematology is often surprisingly normal
considering the presence of alpha thalassaemia.Orphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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Mutation detection
The majority of disease-causing mutations are single base
changes, most of which are missense mutations. The gene
is large and a comprehensive mutation analysis, even of
the coding region alone, is a time-consuming and expen-
sive enterprise. However, the missense mutations are clus-
tered: 50%–60% of the identified mutations are located in
the ADD domain, 20% have the common 736C>T,
R246C mutation and the next most commonly affected
region is the helicase domain. A sensible and cost-saving
approach is to start by analysing these regions.
Protein studies
Levels of ATRX protein were found to be substantially
reduced in a number of patients with missense mutations
involving the ADD domain [23,35]. Analysis of the ATRX
protein may also reveal a truncation in the ATRX protein
of affected individuals, which allows more directed
sequencing.
X inactivation studies
X-chromosome inactivation studies may be used to deter-
mine the carrier status of at-risk women. In normal
women, one X-chromosome is randomly inactivated in
each cell. Most females who are unaffected carriers for
ATR-X syndrome display preferential inactivation of the
mutant ATRX allele [36]. This phenomenon is referred to
as "non-random" or "skewed" X-chromosome inactiva-
tion and can be identified by established laboratory tech-
niques. There are, however, exceptions: a child of normal
intelligence carrying an ATRX  mutation was shown to
have a balanced pattern of X inactivation [36]; another
female carrier with mild mental retardation also had a
non-skewed pattern of X inactivation [37]. This indicates
that there may be a risk of false negative results associated
with this test. Furthermore, 10% of normal females show
skewed X-chromosome inactivation, which could lead to
false positives. Finally, in women with certain X-linked
conditions, other than ATR-X syndrome, the X chromo-
some carrying the mutated gene is preferentially inacti-
vated [38]. Since non-random X-chromosome
inactivation is not unique to ATR-X syndrome, the test is
only supportive, to be used in the context of a suggestive
clinical and/or family history.
Differential diagnosis
Coffin-Lowry syndrome may be confused with ATR-X syn-
drome, particularly in early childhood. Distinguishing
features are the down-slanting palpebral fissures, broad
nose, pudgy tapering digits, absence of genital abnormal-
ities and the frequent presence of carrier manifestations in
Coffin-Lowry syndrome. There is phenotypic overlap with
Angelman syndrome (profound MR with absent speech
and walking, seizures, happy disposition, emotional labil-
ity) and Smith-Lemli-Opitz (facial dysmorphism, skeletal
and genital abnormalities). Diagnostic testing or muta-
tional analysis should allow these conditions to be
excluded in most cases.
Several other syndromes, characterised by the association
of severe mental retardation with dysmorphic features, are
caused by allelic mutations in the ATRX gene: Juberg-Mar-
sidi [34], X-linked mental retardation with spastic para-
plegia [6], Carpenter-Waziri [39], Holmes-Gang [5],
Smith-Fineman-Myers [40] and Chudley-Lowry [31] syn-
dromes.
Genetic counselling and antenatal diagnosis
ATR-X syndrome is a recessive X-linked condition. Female
carriers are usually physically and intellectually normal
and therefore additional tests are required to determine a
female's genotype. In the past, skewed X-inactivation has
been utilised as a marker for carriers of the ATRX muta-
tion; however, for the reasons given above, this method
should be used with caution. Twenty-five percent of obli-
gate female carriers exhibit rare cells with HbH inclusions,
and thus a negative result does not exclude carriage of a
mutation. Since the identification of the ATRX  gene,
mutation detection has become the mainstay of carrier
identification. In families in which the causative mutation
has not been identified, linked markers may be used to
determine whether descendants of an obligate carrier have
inherited the disease-associated haplotype.
For a woman identified as a carrier, there is a 50% risk of
passing on the disease allele but, since only males are clin-
ically affected, the risk of having an affected child is 25%
for each pregnancy. Antenatal diagnosis for such at-risk
females is feasible.
Slide of red blood cells after incubation in brilliant cresyl blue Figure 2
Slide of red blood cells after incubation in brilliant cresyl blue. 
Three cells have Haemoglobin H inclusions giving the cells a 
golf ball like appearance.Orphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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The principal issue when counselling is determining the
risk of recurrence for families with a sporadic case of ATR-
X. One small study showed that 17/20 mothers of spo-
radic cases were carriers [41]. Therefore, in families where
the mutation has not been identified, 85% of the mothers
of sporadic cases would be expected to be carriers.
Another important consideration concerns the possibility
of germline mosaicism. This has been recently reported in
ATR-X syndrome and means that, despite a negative muta-
tion test, a mother of an ATR-X patient may still be at risk
of further affected offspring [41]. It is advisable to offer all
mothers of affected children prenatal diagnosis even if
they are negative for the ATRX mutation.
Management including treatment
Development and behaviour
Evaluation of developmental skills from infancy ensures
that the appropriate intervention services are introduced
as early as possible. Infant stimulation, early intervention
and special education are important to optimise abilities.
Affected individuals may show improvement in socialisa-
tion with one-to-one therapy. Anti-psychotic medication
such as prochlorperazine may be effective in treating
severe behaviour problems.
Feeding and gastro-intestinal problems
Infantile hypotonia is very common and is associated
with considerable difficulty with sucking. Gavage feeding
may be required for a number of weeks to assure adequate
nutrition.
Recurrent vomiting, regurgitation or gastro-oesophageal
reflux, particularly in early childhood, is a common find-
ing and may be secondary to gastric pseudovolvulus. Eval-
uation of recurrent vomiting should include assessment
for gastro-oesophageal reflux and there is a strong case for
24 hr pH monitoring and barium study of the upper gas-
tro-intestinal tract. Initial treatment for gastro-oesopha-
geal reflux should be conservative and standard. Nutrition
consultation for assurance of adequate caloric intake may
be needed. In severe cases, surgical treatment by fundop-
lication may be indicated, as well as the introduction of a
feeding gastrostomy. If gastric pseudovolvulus is demon-
strated this requires surgical correction.
Prolonged periods of food and drink refusal associated
with considerable distress are frequently reported by par-
ents. The cause is rarely obvious, but peptic ulceration,
oesophagitis or ileus should be considered, as these are
well documented in this condition.
Constipation can be a significant management problem
and fecal impaction may occur if preventative measures
are not undertaken. Adequate hydration is important in
preventing constipation, as is the use of bulking agents in
the diet and the regular use of osmotic laxatives such as
lactulose. If the problem is resistant to conservative man-
agement then rectal biopsy should be considered to
exclude ultra-short segment Hirshsprung's disease and
colonic hypoganglionosis.
Drooling is very common in ATR-X, particularly in young
children. Many mothers will describe their sons soaking
several bibs during the course of the day. The open mouth
associated with facial hypotonia no doubt is an important
factor, as is their reluctance to swallow even with a mouth
full of saliva. Numerous methods have been tried to con-
trol drooling. Feeding by mouth may help encourage the
swallowing reflex and this may be supplemented by spe-
cialist training by a speech therapist. In other conditions
in which there is drooling, anticholinergic drugs are com-
monly used to reduce production of saliva. However,
these drugs cause reduced gastrointestinal motility (which
may already be abnormal in ATR-X males) and may exac-
erbate constipation or provoke ileus. Botulinum toxin
type A (Botox) injection of the salivary glands might be
tried, but reports are scant and the treatment needs repeat-
ing. The surgical options of redirecting the submandibular
ducts or removing the glands themselves may be consid-
ered.
Neurologic
Spasticity may increase with age. Regular evaluations of
the need for physical therapy are needed and ongoing
therapy may ameliorate spasticity.
Seizures occur in approximately one third of cases and
most frequently are clonic/tonic or myoclonic in nature.
In the majority of cases, seizures respond well to standard
therapy. Some affected individuals exhibit jerking move-
ments which, though appearing to be seizures, are not
associated with epileptiform activity on EEG. Electroen-
cephalogram may need to be carried out with video
recording to correlate seizure activity and abnormal
movements. Approach to seizure control is standard.
Haematology
In ATR-X syndrome about 90% of cases have alpha thalas-
saemia. The anaemia, however, is mild and does not
require treatment. Iron is not indicated unless iron stores
are shown to be low.
Genitourinary
Genital abnormalities are seen in 80% children. The pos-
sibility of cryptorchidism should be assessed in all
affected children. Orchidopexy should be carried out as
required at the standard age. Intra-abdominal testes,
which are usually dysgenetic, should be removed because
of the long-term risk of malignancy.Orphanet Journal of Rare Diseases 2006, 1:15 http://www.OJRD.com/content/1/1/15
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Structural abnormalities of the kidneys and ureters are
well described and may predispose individuals to urinary
tract infections. Renal abnormalities (hydronephrosis,
renal hypoplasia or agenesis, polycystic kidney, vesico-
ureteric reflux) may present with recurrent urinary tract
infections. The urinary system should be imaged with
ultrasound at diagnosis. Urine should be cultured when
there is symptomatology such as fever or pain on urina-
tion. Prophylactic antibiotics are indicated if urinary tract
anomalies are present to prevent long-term damage to the
kidneys.
Musculoskeletal
A wide range of relatively mild skeletal abnormalities have
been noted, some of which are probably secondary to
hypotonia and immobility [14]. Foot deformities occur in
29% of cases and include pes planus, talipes equinovarus
and talipes calcaneovalgus. Kyphosis and scoliosis are
common and increase with age. A careful musculoskeletal
exam should be done at diagnosis and throughout child-
hood. Treatment of musculoskeletal anomalies, when
appropriate, is standard.
Hearing and vision
Sensorineural deafness may be present. Standard distrac-
tion tests and, if anomalies are suspected, evaluation of
auditory evoked responses should be done. Hearing loss
should be managed as for any infant.
Refractive abnormalities, in particular myopia, are com-
mon. Strabismus may be present. Rarely the children may
be blind and this may be associated with optic atrophy. A
formal ophthalmologic evaluation is appropriate at diag-
nosis and regularly thereafter. Ocular problems should be
treated as in the general population.
Prognosis
Among the 168 patients described, there have been 25
deaths. The cause was established in just over half of these
cases: there were six cases of pneumonia and four due to
aspiration of vomitus. Patients appear to be particularly
vulnerable in early childhood, with 19 of the deaths
occurring under the age of five years. This may be associ-
ated with the fact that gastro-oesophageal reflux and vom-
iting are often more severe in the early years. In two cases,
death was associated with renal failure, which was possi-
bly due to recurrent renal tract infection. There are no
long-term longitudinal data for this relatively newly
described syndrome but a number of affected individuals
are fit and well in their 30s and 40s.
Unresolved questions
1. The function of ATRX protein is not known. It is not
clear how loss of function mutations in a protein associ-
ated with repressive heterochromatin might lead to
reduced expression of a target gene (e.g. alpha globin).
The role of ATRX in DNA methylation is also unknown.
2. What are the 'target' genes whose expression is directly
influenced by ATRX? How are these genes related to the
observable phenotype?
3. Why is there variability in the features of the phenotype,
for example, the presence and severity of alpha thalassae-
mia is variable even for a given mutation and it seems
likely that modifying genes are involved. Obvious candi-
dates are genes encoding other protein components of
heterochromatin.
4. What is the prevalence of ATR-X syndrome?
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